Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: HerefordRibSteak who wrote (3251)	2/26/2014 12:12:31 PM
From: jaybe	Respond to of 4474

I have a (rough) guess below but an accurate answer would be quite complicated... MET/RON - $1-2B peak WW annual Her2/Her3 - $2-3B peak WW annual EGFRm 2L (shelved candidate) - $1-2B peak WW annual MET is amplified/mutated in approx. 4% on NSCLC, 10% of CRC, and 20% of gastric, but MET is highly indicated for metastatic progression in several major cancers including breast, colorectal, renal cell carcinoma, lung, and gastric. So a potent, pan-MET(RON) inhibitor could be used in numerous combinations with Mabs in advanced stage cancers. Current MET TKIs such as tivantinib, carbozantinib, and foretinib leave plenty of room for a next-gen to be best in class. Her2 is indicated in 20-25% of breast, lung, prostate, gastric, and ovarian. If a TKI could prevent Her2 from dimerizing with Her3 and Her1(EGFR) then it could also be used in combination with other therapies in something like 20-30% of most cancers. Current TKIs lapatinib and afatinib also leave room for best-in-class, largely approved as combination therapy with the more effective Mabs.